ANVS Stock Summary and Trading Ideas (Annovis Bio | NYSE:ANVS)

Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.

Annovis Bio trades on the NYSE stock market under the symbol ANVS.

As of March 20, 2026, ANVS stock price declined to $2.60 with 696,910 million shares trading.

ANVS has a beta of 2.34, meaning it tends to be more sensitive to market movements. ANVS has a correlation of 0.14 to the broad based SPY ETF.

ANVS has a market cap of $73.72 million. This is considered a Micro Cap stock.

In the last 3 years, ANVS traded as high as $23.89 and as low as $1.11.

The top ETF exchange traded funds that ANVS belongs to (by Net Assets): VTI, VXF.

ANVS has outperformed the market in the last year with a price return of +42.1% while the SPY ETF gained +15.6%. However, in the short term, ANVS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -28.8% vs -4.7% return in SPY. But in the last 2 weeks, ANVS shares have fared better than the market returning +4.8% compared to SPY -4.8%.

ANVS support price is $2.52 and resistance is $2.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANVS shares will trade within this expected range on the day.